4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.79) per share. This is a 3.66 percent increase over losses of $(0.82) per share from the same period last year.
The AZEK Company Sees Q1 Revenue $230M-$236M Vs $247.35M Est.; FY24 Revenue $1.335B-$1.395B Vs $1.43B Est.
OUTLOOKAZEK provides certain of its outlook on a non-GAAP basis, as the Company cannot predict some elements that are included in reported GAAP results, including the impact of acquisition costs and other costs. Refer to
